MARKET

IVA

IVA

Inventiva S.A.
NASDAQ
3.240
-0.050
-1.52%
After Hours: 3.250 +0.01 +0.31% 16:00 04/24 EDT
OPEN
3.120
PREV CLOSE
3.290
HIGH
3.297
LOW
3.050
VOLUME
13.29K
TURNOVER
0
52 WEEK HIGH
5.05
52 WEEK LOW
2.220
MARKET CAP
168.86M
P/E (TTM)
-1.2056
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at IVA last week (0415-0419)?
Weekly Report · 2d ago
Hepion ends Phase 2 study for NASH drug due to cash restraints
Seeking Alpha · 5d ago
Weekly Report: what happened at IVA last week (0408-0412)?
Weekly Report · 04/15 10:42
Madrigal announces US launch of NASH/MASH drug Rezdiffra
Healthcare Madrigal announces US launch of NASH/MASH drug Rezdiffra. The drug is now available in the US through a specialty pharmacy network. Other companies working on therapies for NASH and MASH include Eli Lilly and Novo Nordisk. MadrigAL is the first to receive FDA approval for the treatment of the disease.
Seeking Alpha · 04/09 14:03
Inventiva Is Maintained at Buy by Canaccord Genuity
Dow Jones · 04/08 11:54
Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), CervoMed (CRVO) and Teladoc (TDOC)
TipRanks · 04/08 11:30
Weekly Report: what happened at IVA last week (0401-0405)?
Weekly Report · 04/08 10:46
Inventiva’s Latest Move: Issuing Royalty Certificates That Could Dilute Lanifibranor Earnings
TipRanks · 04/04 06:00
More
About IVA
Inventiva SA is a France-based company engaged in the biotechnology sector. The Company focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.

Webull offers Inventiva SA stock information, including NASDAQ: IVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IVA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IVA stock methods without spending real money on the virtual paper trading platform.